Fig. 4

Cumulative incidence of breast cancer recurrence or death by androgen receptor/estrogen receptor (AR/ER) ratio (less than 1 [black line] vs. 1 or more [red line]) for the tamoxifen cohort (A) and the tamoxifen + fluoxymesterone cohort (B)